Document Actions
J&J To Eliminate Ortho Biotech Unit
From The Cancer Letter, May 2, 2008:
Johnson & Johnson is eliminating the separate business unit Ortho Biotech, which has developed the market for erythropiesis-stimulating agents by claiming in direct-to-consumer advertising that they improved cancer patients’ quality of life.On April 29, the company told its employees that Ortho Biotech would be combined with another J&J company, Centocor Inc., which markets the agent Remicade, a treatment for autoimmune diseases, now the company’s highest grossing drug.
Click on The Cancer Letter Archive at left to download the May 2 issue (subscription required).
_____
tags:
Friday, May 02, 2008
in
drug development
| Permalink |
Comments (0)
trackback URL: http://www.cancerletter.com/tcl-blog/copy46_of_whats-going-on-with-nih/sbtrackback
Forgot your password?